KPV’s Anti-Inflammatory Effect Is Real Science. Its Human Safety Record Is a Blank Page.
KPV's anti-inflammatory effect is real, published, mechanistic science: it works through a different pathway than the melanocortin receptors that give its parent hormone its pigmentation effect. FDA staff reviewed it in July 2026 and found zero human studies, in any form, for any use, then recommended against adding it to the compounding list. The FDA's own advisory panel voted otherwise, by a narrow margin, in favor of allowing it to be compounded anyway. Neither vote is an approval, and the underlying human-data problem staff flagged hasn't gone anywhere.
Reviewed by the PepGuard team · Last reviewed Jul 28, 2026
Tripeptide (lysine-proline-valine), the C-terminal sequence of alpha-melanocyte-stimulating hormone · also called Lys-Pro-Val, alpha-MSH C-terminal tripeptide
Photo: Eduardo Cano Photo Co. / UnsplashKPV and Melanotan II come from the same hormone. They don’t work the same way.
Both peptides trace back to alpha-melanocyte-stimulating hormone (alpha-MSH). Melanotan II is built to activate melanocortin receptors, the same receptors responsible for pigmentation, which is exactly why it tans people. KPV is the opposite end of the same hormone: just its C-terminal three amino acids, lysine-proline-valine.
A 2003 mechanism study tested the two head-to-head in mice. Melanotan II (labeled MTII in that paper) needed functional melanocortin receptors to produce its anti-inflammatory effect. KPV didn’t: its effect persisted even in mice bred with a nonfunctional melanocortin-1 receptor, and researchers concluded KPV “is unlikely to mediate its effects through melanocortin receptors,” pointing instead to a separate pathway involving interleukin-1beta. That’s a real, specific, published pharmacological finding, not a marketing claim. It says nothing about whether KPV is safe or effective as something a person injects, swallows, or rubs on their skin.
Real anti-inflammatory signals. In mice and cell dishes, not people.
The most commonly cited KPV evidence is a 2008 paper on intestinal inflammation. In mice with chemically induced colitis, KPV reduced a marker of colon inflammation (myeloperoxidase activity) by roughly half, in an experiment using five mice per group. In human intestinal cells grown in a dish, a 10 nanomolar concentration of KPV cut an inflammatory signal (IL-8 mRNA, triggered by IL-1beta) by about 35%. Both results are consistent with the mechanism above: a real anti-inflammatory effect, demonstrated in the systems it was actually tested in.
Neither result is a human outcome. A five-mouse colitis experiment and a cell-culture dish are not a clinical trial, and nothing in either paper establishes what, if anything, KPV does when a person takes it.
There is no human dose. Here’s what was actually studied.
| What's cited | Range |
|---|---|
| Established human clinical dose | None |
| Cell experiment | 10 nM KPV in stimulated intestinal epithelial cells |
| Mouse colitis model | 100 micromolar KPV in drinking water |
No human dosing regimen is established by a clinical trial. Preclinical concentrations and animal exposures are listed only to show what was studied in the source literature; they cannot be converted into a human injection, capsule, or 'units' protocol.
Not “limited” human data. Zero.
In July 2026, the FDA evaluated a compounding nomination for KPV and searched for any human data on it: published studies, pharmacokinetic data, case reports, and adverse-event reports in its own FAERS database going back to 2004. It found nothing. Its own briefing document states it plainly: “The nomination did not include, and FDA did not find any information on the use of KPV (free base) or KPV acetate administered in humans.” A dedicated search of FAERS through December 3, 2025 returned zero adverse-event reports naming KPV, in either direction, good or bad. That’s not evidence of safety. It’s confirmation that no one is tracking what happens when a person takes it.
Reported where, exactly.
| Signal | Frequency | Context |
|---|---|---|
| Human adverse-event profile | unknown / not studied | The core cited study used cell lines and mouse models, not a human safety trial. |
| Product identity and contamination risk | unknown / not studied | Preclinical findings do not verify the purity, concentration, sterility, or contents of a commercial KPV product. |
FDA proposed against adding KPV to the compounding list.
The cited KPV evidence includes cell experiments and mouse colitis models. Those experiments can generate a mechanism hypothesis, but they do not establish clinical efficacy, safety, oral absorption in people, or a dose for a supplement or injection. FDA's Pharmacy Compounding Advisory Committee evaluated a nomination for KPV (free base) and KPV acetate at its July 23, 2026 meeting (the nomination itself, from Wells Pharmacy Network, had already been withdrawn; FDA proceeded with a full evaluation anyway). FDA staff's conclusion, verbatim: "The nomination did not include, and FDA did not find any information on the use of KPV (free base) or KPV acetate administered in humans." A search of the FDA Adverse Event Reporting System (FAERS) through December 3, 2025 returned zero reports naming KPV. On that basis, FDA staff recommended KPV (free base) and KPV acetate NOT be included on the 503A Bulks List, citing a lack of chemical characterization, a lack of any effectiveness data, and a lack of any safety data in humans. The advisory panel didn't follow that recommendation: per independent reporting from NPR and CBS News, it voted, by narrow margins and against its own staff's advice, to recommend adding KPV to the compounding-eligible list, one of six peptides (alongside BPC-157, MOTS-c, TB-500, Epitalon, and Semax) to receive a favorable vote that day; only Emideltide (DSIP) was voted down. The FDA isn't required to follow its advisory committee's recommendation, but typically does, and has not yet acted on it as of this writing. A panel vote is not an FDA decision, and neither changes the underlying finding: zero human studies of KPV exist.
KPV and Melanotan II split from the same hormone, then split apart
Both trace back to alpha-melanocyte-stimulating hormone. Melanotan II keeps and amplifies the melanocortin-receptor activity that drives pigmentation. KPV, the hormone's C-terminal fragment, was found to produce its anti-inflammatory effect largely without that same receptor pathway. Shared ancestry, different mechanism, different evidence problems.
Every claim above, traced back.
The mechanism study, the colitis and cell-culture papers, and the FDA’s own July 2026 review. Click through and check them yourself.
KPV questions, answered.
The evidence for a benefit is preclinical: in mouse models, KPV reduced markers of colitis and general inflammation, and in cell experiments it blunted an inflammatory cytokine response. That is a real, published pharmacological effect in animals and cell systems. It has never been tested as a treatment in a person, so there is no human-confirmed benefit, dose, or outcome to report.
No, and the difference is the most well-documented thing about KPV. Melanotan II is built to activate melanocortin receptors, which is what produces its pigmentation (tanning) effect. The founding mechanism study on KPV tested it head-to-head against Melanotan II (called MTII in that paper) and found KPV's anti-inflammatory effect persists even in mice with a nonfunctional melanocortin-1 receptor, and concluded KPV "is unlikely to mediate its effects through melanocortin receptors." They're derived from the same parent hormone but work through different pathways for different purposes.
No human clinical dose has been established. Online charts are not a substitute for a dose-ranging human study and should not be presented as a validated protocol.
A key 2008 paper found anti-inflammatory signals in cell systems and mouse colitis models. It did not test KPV as a treatment in people.
No. There's no FDA-approved KPV medicine or indication, and no vote or recommendation changes that. FDA went further than a routine review in July 2026: reviewing a compounding nomination for KPV, its own scientific staff found zero published human studies and zero FAERS adverse-event reports, and recommended against adding it to the compounding-eligible substance list. That's a separate question from FDA approval either way, an approval requires actual clinical trials, which don't exist for KPV.
Yes, at a July 23, 2026 Pharmacy Compounding Advisory Committee meeting. FDA's own briefing document states plainly: "The nomination did not include, and FDA did not find any information on the use of KPV (free base) or KPV acetate administered in humans." FDA staff recommended KPV not be added to the 503A compounding list on that basis. The advisory panel disagreed: per NPR and CBS News' independent reporting, it voted by a narrow margin to recommend adding KPV anyway, against its own staff's advice, one of six peptides to get a favorable vote that day. That's an advisory recommendation, not an FDA decision, and the FDA has not yet acted on it as of this writing. The committee's formal meeting minutes have not yet been published, only the journalism covering the vote itself.
Keep researching.
This is a preview of the KPV report.
Create your account to check any peptide against the full research base.